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6 and MJ Whalen*
,1,2
Necroptosis is a newly described form of regulated necrosis that contributes to neuronal death in experimental models of stroke
and brain trauma. Although much work has been done elucidating initiating mechanisms, signaling events governing
necroptosis remain largely unexplored. Akt is known to inhibit apoptotic neuronal cell death. Mechanistic target of rapamycin
(mTOR) is a downstream effector of Akt that controls protein synthesis. We previously reported that dual inhibition of Akt and
mTORreducedacutecelldeathandimprovedlongtermcognitivedeﬁcitsaftercontrolled-corticalimpactinmice.Theseﬁndings
raised the possibility that Akt/mTOR might regulate necroptosis. To test this hypothesis, we induced necroptosis in the
hippocampal neuronal cell line HT22 using concomitant treatment with tumor necrosis factor a (TNFa) and the pan-caspase
inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-ﬂuoromethylketone. TNFa/zVAD treatment induced cell death within 4h. Cell death
was preceded by RIPK1–RIPK3–pAkt assembly, and phosphorylation of Thr-308 and Thr473 of AKT and its direct substrate
glycogen synthase kinase-3b, as well as mTOR and its direct substrate S6 ribosomal protein (S6), suggesting activation of Akt/
mTOR pathways. Pretreatment with Akt inhibitor viii and rapamycin inhibited Akt and S6 phosphorylation events, mitochondrial
reactiveoxygenspeciesproduction,andnecroptosisbyover50%withoutaffectingRIPK1–RIPK3complexassembly.Thesedata
were conﬁrmed using small inhibitory ribonucleic acid-mediated knockdown of AKT1/2 and mTOR. All of the aforementioned
biochemical events were inhibited by necrostatin-1, including Akt and mTOR phosphorylation, generation of oxidative stress,
andRIPK1–RIPK3–pAktcomplexassembly.Thedatasuggestanovel,heretoforeunexpectedroleforAktandmTORdownstream
of RIPK1 activation in neuronal cell death.
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Necroptosis is a form of programmed necrosis regulated by
the kinase activity of receptor-interacting protein kinase 1
(RIP1; also known as RIPK1) and RIP3 (also known as
RIPK3). Necroptotic stimuli induce TNF receptor 1 complex
assembly involving TNFR- associated death domain protein,
Fas-associated death domain protein, caspase-8, RIPK1,
RIPK3, and various regulator molecules such as FADD-like
interleukin-1 beta converting enzyme (FLICE)-like inhibitory
protein and cylindromatosis protein, among others. The
complex formed by RIPK1–RIPK3 deﬁnes the necrosome,
which is required for initiation of necroptotic cell death.
1
Necroptosis contributes to neuronal death in experimental
models of stroke and traumatic brain injury.
2,3 Recently,
intensive research effort has been directed towards elucidat-
ing mechanisms that contribute to necroptosis execution,
revealingcritical rolesforthekinaseactivityofRIP1andRIP3,
as well as the presence of the mixed lineage kinase domain-
like protein,
4,5 the mitochondrial ﬁssion protein regulator
dynamin-related protein-1
6 and reactive oxygen species
(ROS).
2 RIPK1 activity and necrosome complex assembly is
regulated by ubiquitylation and deubiquitylation reactions
mediated by cylindromatosis protein
7 and others. Although a
number of reports have elucidated mechanisms of necropto-
sis initiation, little is known about the signaling and execution
mechanisms downstream of the necrosome, and how
necroptosis is governed in neuronal cells remains unex-
plored.
8–10
We recently reported that, surprisingly, combination-phar-
macological inhibition of Akt and mechanistic target of
rapamycin (mTOR) reduced necrotic cell death in CA3 and
CA1 regions of hippocampus and improved functional
outcome after controlled-cortical impact (CCI) in mice.
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www.nature.com/cddisThese observations, along with our previous data suggesting
the contribution of RIP1 kinase-dependent necroptosis to
CCI,
3 suggested a possible role for Akt/mTOR signaling in
programmed necrosis in neuronal cells. These in vivo studies
in the mouse CCI model prompted us to examine directly
whether Akt and mTOR mediate programmed necrosis in
neuronal cells. To this end, we used hippocampal HT22 cells
to test the hypothesis that RIPKI–RIPK3 mediated necropto-
sis is regulated downstream of necrosome assembly by Akt
and mTOR. Herein, we report activation of Akt/mTOR
signaling pathways and neuronal cell death that are inhibited
by pharmacologic or genetic inhibition of Akt and mTOR
together. Inhibition of Akt/mTOR did not affect necrosome
complex assembly but inhibited oxidative stress and cell
death. The data suggest an unexpected role for Akt/mTOR in
the regulation of neuronal necrosis. Given a large number of
Akt and mTOR inhibitors currently under development, this
mechanism of acute neuronal cell death could be highly
amenable for therapeutic intervention.
Results
TNFa/zVAD induces necrosis in HT22 cells. To assess
signaling pathways that might mediate necroptosis down-
stream of RIPK1, we began by establishing conditions
that induce necroptosis in HT22 cells using tumor necrosis
factor-a (TNFa) and zVAD administration. Dose–response
studies of TNFa and zVAD separately determined optimal
concentrations of each reagent that together promote
necroptosis (Figure 1). We found that 1ng/ml TNFa and
50mM zVAD efﬁciently induced cell death and, therefore,
these conditions were used subsequently in all experiments
(Figures 1a–c). TNFa/zVAD treatment induced membrane
permeability to propidium iodide (PI) (Figure 1c) as well as
Figure 1 TNFa/zVAD induces necrosis in HT22 cells. (a, b) TNFa and zVAD dose–response curves. Cell death was assessed by propidium iodide (PI) and Hoechst
staining. (c) Representative images of HT22 cells treated with DMSO or TNFa (1ng/ml)/zVAD (50mM) for 4h. (d) HMGB1 translocation was detected in cells (blue: Hoechst
dye; green: HMGB1 antibody), and in culture media by western blot. (e) Transmission electron microscopy of HT22 cells treatedwith TNFa/zVAD for 4 or 24h shows necrotic
morphology including swollen mitochondria, cytoplasmic clearing, membrane damage, and chromatinolysis. M, mitochondrion; N, nucleus. (All data are presented
as mean±S.E.M. from 3–5 independent experiments. *Po0.05; **Po0.01; ***Po0.001 versus DMSO group.) Scale bars: c, 100mm; d, 10mm; e, 1mm
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Cell Death and Diseaseearly translocation of high mobility box group-1 protein
(HMGB1) from nucleus to cytosol (Figure 1d), suggesting
necrosis. Electron microscopy conﬁrmed ultrastructural
features of necrosis including swollen mitochondria, cyto-
plasmic clearing, membrane damage, and characteristic
nuclear changes (Figure 1e). Thus, HT22 cells die by
necrosis in response to TNFa/zVAD.
TNFa/zVAD-induced cell death in HT22 cells is
necroptosis. To determine whether TNFa induces necrop-
tosis, for example, RIPK1/RIPK3-dependent programmed
necrosis, HT22 cells were treated with TNFa/zVAD in the
presence or absence of the potent and speciﬁc RIPK1
inhibitor 7-Cl-O-necrostatin-1 (referred to as Nec-1 here-
after), an optimized analog of necrostatin-1 that showed no
off-target inhibitory activity in a screen of over 400 human
kinases.
12–14 Nec-1 dose dependently inhibited cell death in
response to TNFa/zVAD (Figures 2a and b). To further
validate the role of Nec-1, we used an N-methyl inactive
analog of 7-Cl-O-necrostatin-1 that lacks inhibitory activity
12
and showed that cell death was no longer inhibited, strongly
suggesting that HT22 cell death was necroptosis. To further
pursue necroptosis as the speciﬁc mode of death we
employed genetic knockdown of RIPK3 using speciﬁc small
inhibitory ribonucleic acid (siRNA). Figure 2 shows robust
reduction of RIPK3 protein after 72h treatment with RIPK3-
speciﬁc siRNA and potent inhibition of TNFa/zVAD-induced
cell death, strongly suggesting involvement of both RIPK1
and RIPK3 together in HT22 necrosis (Figures 2c and d).
Necroptosis in non-neuronal cells requires formation of a
RIPK1–RIPK3 necrosome complex that is dependent on the
kinase activity of RIPK1 and RIPK3.
15–17 To assess for
necrosome assembly, we performed immunoprecipitation
(IP) experiments that conﬁrmed interaction between RIPK1–
RIPK3. RIPK1/RIPK3 complex formation was inhibited by
Nec-1, as previously reported in non-neuronal cell lines.
15
Figure 2 Cell death induced by TNFa/zVAD in HT22 cells is necroptosis. (a) Dose dependent inhibition of TNFa/zVAD-induced cell death by necrostatin-1. Data are
mean±S.E.M.from three independent experiments. *Po0.01; **Po0.001 versusTNFa (1ng/ml)/zVAD (50uM) (TZ) alone. (b) Thespeciﬁc RIPK1kinase inhibitor, 7-Cl-O-
necrostatin-1 (Nec-1) but not inactive analog (7-Cl-O-Nec-1; Nec-1i) prevented cell death induced by TNFa and zVAD. p¼ns TZ versus TZ Nec-1i. (c) Knockdown of RIPK3
by speciﬁc siRNA suppressed TNFa/zVAD-induced cell death. *Po0.001 versus negative siRNA treated with TNFa/zVAD. (d) Western blot analysis of RIPK3 knockdown.
(e)Representativeimmunoprecipitationexperiment(n¼3)showingRIPK1–RIPK3complexassemblyinTNFa/zVAD-treatedHT22cells.Complexassemblywasinhibitedby
Nec-1. T, TNFa (1ng/ml); TZN, TNFa (1ng/ml)/zVAD (50mM)/Nec-1(30mM). Data are mean and S.E.M. of three independent experiments
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Cell Death and DiseaseInhibition of RIPK1/RIPK3 interaction by Nec-1 was not
explained by a reduction in protein level as shown by western
blot of input sample homogenates (Figure 2e). From these
experiments, we conclude that HT22 cell death in response
to TNFa/zVAD is necroptosis, in this case dependent
upon both RIPK1 and RIPK3, and that at least part of the
protective effects of necrostatin-1 involves inhibition of
RIPK1/RIPK3 complex assembly.
Necroptosis in HT22 cells is dependent on ROS. Necrop-
tosis in some, but not all, cell lines has been shown to
depend on generation of ROS.
2,16,18 To determine whether
generation of ROS has a role in TNFa/zVAD-induced
necrosis in HT22 cells we used Mitosox red, which detects
mitochondrial ROS as well as a number of other potential
ROS species.
19 Mitosox-positive cells were increased by
TNFa/zVAD treatment and this increase was strongly
inhibited by Nec-1, indicating that ROS are generated
downstream of RIPK1 (Figures 3a and b). ROS generation
was also inhibited by Akt viii/rapamycin, suggesting Akt and
mTOR signaling is upstream of ROS production (Figures 3a
and b). ROS generation (not shown) and HT22 cell death
(Figure 3c) was dose dependently inhibited by the antiox-
idant betahydroxyanisole, and cell death was blocked by a
number of other antioxidants including rotenone (a mitochon-
drial complex I inhibitor) and the lipoxygenase inhibitor
baicalein (Bai; Figure 3c). Another lipoxygenase inhibitor
that does not have antioxidant activity itself but is known
to reduce oxidative stress-related cell death in HT22
cells, LOXBlock-1 (LOX-1),
20,21 also protected against
TNFa/ZVAD to the same extent as bai and rotenone. Thus,
ROS generation is required for necroptosis in HT22 cells.
TNFa/zVAD activates Akt and mTOR signaling pathways
in HT22 cells. Curiously, previous studies in cancer cells
suggested that Akt activity may promote, rather than inhibit
ROS-induced cell death due to transcriptional downregula-
tion of antioxidant defenses. Our recent study suggested that
in a speciﬁc case of mouse ﬁbrosarcoma L929 cell line
Akt and mTOR activation contributes to necroptosis.
22–24
However, this was not observed in a number of other cell
lines, where Akt was linked to TNFa synthesis but not cell
death, suggesting that pronecroptotic signaling may be
limited to L929 cells. However, given our previous data
regarding the roles of Akt and mTOR in CCI, we assessed for
activation of Akt and mTOR pathways in TNFa/zVAD-treated
HT22 cells at 2h. We chose this early time point because it is
before the onset of detectable cell death in our model
system. In response to TNFa/zVAD, Akt was phosphorylated
at the 473 and 308 sites along with glycogen synthase kinase
(GSK)-3b (Ser9), a direct substrate of Akt, and mTOR and its
direct substrate S-6 (Figures 4a and c). In contrast to L929
cells induced to necroptosis by TNFa alone in which Akt
phosphorylation was transient early on but sustained several
Figure 3 Cell death induced by TNFa/zVAD is associated with oxidative stress. (a) Representative  200 photomicrographs showing MitoSox Red and Hoechst
ﬂuorescence in HT22 cells 4h after treatment with dimethylsulfoxide vehicle (DMSO), TNFa/zVAD (TZ), or TNFa/zVAD treatment in the presence or absence of Akt/mTOR
inhibitors(TZAR,TZþAktinhibitorVIII(10uM)þrapamycin(100nM))ornecrostatin-1(30uM;TZN).(b)MitoSox-positivecellswerequantitatedbyﬂuorescencemicroscopy.
ANOVAPo0.0001.*Po0.05versusTZforallgroups.Dataarefromfourindependentexperiments.(c)Protectiveeffectsofbetahydroxyanisole(BHA),LOXBlock-1(LOX-1)
inhibitor, baicalein, and rotenone on TNFa/zVAD-induced cell death. Data are from three independent experiments. *Po0.05; **Po0.01 versus TNFa/zVAD (TZ) group.
TZN, TNFa/zVAD/Nec-1 (30mM)
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Cell Death and Diseasehours later,
23 Akt and mTOR phosphorylation in HT22
cells was detectable as early as 30min after addition of
TNFa/zVAD and was sustained throughout the entire
experimental period (Figures 4a and c and data not shown).
Phosphorylation of Akt and mTOR and their related
substrates was not induced by TNFa or zVAD alone but
required speciﬁc necroptotic signaling by TNFa/zVAD
together (Figures 4b and d). Necrostatin-1 pretreatment
inhibited the increase in Akt-308 and -473, as well as that
of mTOR and Akt and downstream mTOR substrates,
conﬁrming that phosphorylation and activation of Akt/mTOR
in response to TNFa/zVAD is RIPK1 dependent and
represent sequelae of necroptosis signaling downstream
from RIPK1 (Figures 5b and c). Notably, treatment of HT22
cells with TNF/cyclohexamide (CHX) induced widespread
death by 18h but did not induce Akt phosphorylation at 2h
(Figure 4e) or 18h (data not shown), suggesting that Akt
activation in HT22 cells treated with TNF/zVAD is speciﬁc
for necroptosis.
To test functionality of Akt and mTOR activation, we used
twodifferent approaches.First, we treatedHT22 cellswithAkt
inhibitor viii, rapamycin, or both and assessed cell death by PI
staining and pathway inhibition by western blot. Administra-
tion of Akt and mTOR inhibitors together reduced HT22 cell
death to a greater extent than Akt or mTOR inhibitors alone,
suggesting that both pathways participate in necroptosis
signaling (Figure 5a). Cell death was also reduced by
treatment with Akt inhibitor viii and torin II, a more
speciﬁc inhibitor of mTOR than rapamycin (data not shown).
Western blot and densitometric analyses conﬁrmed
inhibition of phosphorylation of Akt and mTOR and their
substrates by Akt inhibitor viii and rapamycin, respectively
(Figures 5b and c).
In a second approach to mitigate the potential problem
of off-target effects that could confound interpretation
of pharmacological experiments, we used speciﬁc siRNA to
knockdown Akt 1 and 2 (Akt 3 was not detected in HT22 cells;
Figure 6a) and mTOR (Figures 6b and c), and assessed the
effect of genetic inhibition of each in TNFa/zVAD-induced cell
death. In each case robust knock down of protein was
obtained, and HT22 cells administered siRNA against Akt1/2
and mTOR together had reduction in TNFa/zVAD-induced
death similar in magnitude to treatment with chemical Akt and
mTOR inhibitors (Figure 6d). Thus, chemical and genetic
approaches each suggested a role for Akt and mTOR
activation in programmed necrosis of HT22 cells.
Akt/mTOR inhibition does not affect RIPK1–RIPK3
complex assembly in TNFa/zVAD-treated HT22 cells.
Previous studies have demonstrated an essential role for
Figure 4 Activation of Akt/mTOR after TNFa/zVAD treatment. Representative immunoblots (a, b) and densitometry results (c, d) of Akt/mTOR activation in HT22 cells
after TNFa/zVAD or vehicle dimethylsulfoxide treatment. (a) Time course of phosphorylation events downstream of Akt/mTOR (n¼3 independent experiments).
(c) Densitometry data from a.( b) Synergistic effect of TNFa and ZVAD is required to activate Akt/mTOR signaling in HT22 cells. (d) Densitometry data from b.
(e) Representative western blot analysis of Akt phosphorylation 2h after treatment with TNF/cyclohexamide to induce apoptotic cell death. No change in pAkt-473 or total Akt
was observed using apoptotic stimuli. *Po0.05; **Po0.01; ***Po0.001 versus DMSO group. Data are from n¼3 independent experiments. Abbreviations: phospho-Ser-
473-Akt (p-Akt-473), phospho-Ser308-Akt (p-Akt-308), phospho-Ser9-GSK-3b (p-GSK-3b), phospho-Ser2448-mTOR (p-mTOR) and phospho-Ser235/236 S6 (p-S6)
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Cell Death and Diseasekinase activity of RIPK1/RIPK3 in assembly of the necro-
some complex.
4,15–17 To determine whether Akt/mTOR
activation might also have a role in RIPK1/RIPK3 complex
assembly, HT22 cells were treated with TNFa/zVAD in the
presence or absence of Akt inhibitor viii and rapamycin, and
RIPK1–RIPK3 interaction was assessed by IP. Akt/mTOR
Figure 5 Dual inhibition of Akt and mTOR inhibits necroptosis induced by TNFa/zVAD. (a) Akt and mTOR inhibitors reduced cell death induced by TNFa/zVAD as
detectedbypropidiumiodide(PI)andHoechststaining.(b,c)RepresentativeimmunoblotsanddensitometryforphosphorylatedAkt,GSK-3b,FoxO1,mTOR,andS6inHT22
cells after TNFa/zVAD in the presence or absence of Akt inhibitor VIII (10uM) and rapamycin (100nM) (data are three independent experiments, *Po0.01; **Po0.001
compared with TZ group). Abbreviations: TNFa (1ng/ml)/zVAD (50mM)/Akt inhibitor VIII (10mM) (TZA), TNFa (1ng/ml)/zVAD (50mM)/rapamycin (100nM) (TZR),
TNFa (1ng/ml)/zVAD (50mM)/Akt inhibitor VIII (10mM)/ rapamycin (100nM) (TZAR)
Figure 6 Knockdown of Akt and mTOR inhibits necroptosis induced by TNFa/zVAD. (a) HT22 cells expressed Akt1 and Akt2 but not Akt3 determined by immunoblot.
Mouse lung ﬁbroblasts were used as Akt3 positive control. (b, c) siRNA-mediated knockdown of mTOR, Akt1, and Akt2 in HT22 cells was conﬁrmed by immunoblot using
reagents identifyingtotal Akt and mTOR. (d) Cell death was determined in control cells and in cells with knockdown of Akt1/2, mTOR, or triple knockdown of mTOR and Akt1/
Akt2 together. Data are representative of three independent experiments, *Po0.05 versus control (CTL) siRNA
Akt and mTOR in necroptosis
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Cell Death and Diseaseinhibition did not affect RIPK1–RIPK3 interaction (Figure 7a),
suggesting that Akt/mTOR activation occurs downstream of
RIPK1–RIPK3 complex assembly and prior to necroptosis
steps that produce oxidative stress. These data also raised
the possibility of direct interaction of Akt with the necrosome
and regulation of its phosphorylation and activation
by RIPK1. Indeed, total Akt as well as phospho–Akt–473
was detected in RIPK1 immunoprecipitants in TNF/ZVAD-
stimulated HT22 cells, and phospho–Akt–473 interaction
with RIPK1 was undetectable with pretreatment of cells with
necrostatin-1 (Figures 7b and c). Inhibition of pAkt–RIPK1
interaction by Nec-1 was not due to lack of RIPK1 protein as
conﬁrmed by IP (Figure 7c). These data suggest that Akt
complexes with RIPK1 and RIPK3, and that its activity during
necroptosis may be regulated by necrosome activity.
Discussion
Elucidating mechanisms of neuronal necroptosis is an
important area of investigation considering the growing
number of reports suggesting its involvement in acute central
nervous system injury, including ischemia/reperfusion,
trauma, and intracerebral hemorrhage.
2,3,25,26 Despite a
signiﬁcant research effort to characterize the molecular
machinery of necroptosis, little is known regarding
the components of necroptosis signaling downstream of
necrosome assembly, and almost nothing is known about
the regulation of necroptosis in neuronal cells.
8–10 Necropto-
sis in HT22 cells exhibited all of the cellular and biochemical
features of necrosis reported in non-neuronal cells including
assemblyofaRIPK1–RIPK3necrosomecomplex,generation
of ROS, sensitivity to Jun-N-kinase (JNK) and ROS
inhibitors,
2,23,27,28 loss of mitochondrial membrane potential
and adenosine triphosphate depletion, and characteristic
ultrastructural features.
2,15–17 Protection by the speciﬁc
RIPK1 inhibitor 7-Cl-O-necrostatin-1 and by RIPK3 knock-
down conﬁrmed necroptotic cell death in this model system.
We previously reported that pharmacological inhibition of
Akt and mTOR reduced early cell death in CA1 and CA3 after
CCI in mice, suggesting a novel role for Akt and mTOR in the
pathogenesis of traumatic brain cell death.
11 These observa-
tions prompted us to examine the role of Akt and mTOR in
necroptosis signaling in neuronal cells. We found that
administration of TNFa/zVAD (but not TNFa or zVAD alone)
induced rapid and sustained phosphorylation of Akt on
Thr-308 and Ser-473 and mTOR, as well as phosphorylation
of direct substrates of Akt (GSK-3b, forkhead box class
O (FOXO)-1) and mTOR (S6 ribosomal protein (S6)). All of
these phosphorylation events were inhibited by necrostatin-1,
a potent and highly speciﬁc RIPK1 inhibitor.
12 IP experiments
showed that TNF/ZVAD induced RIPK1–Akt and RIPK1–
pAkt-473 interaction. Necrostatin-1 treatment rendered
RIPK1–pAkt-473 interaction undetectable, consistent with
inhibition of phosphorylation of Akt by the necrosome.
Alternatively, necrostatin-1 may prevent binding of Akt to
RIPK1. To our knowledge, the data are the ﬁrst to show a
direct interaction of Akt with RIPK1, and provide a molecular
link between necrosome assembly and Akt activation during
neuronal necroptosis.
Akt/mTOR inhibition did not affect RIPK1–RIPK3 interac-
tion but inhibited ROS production and cell death. Importantly,
genetic inhibition of Akt and mTOR together reduced cell
death by a magnitude similar to that of pharmacological
inhibitors, conﬁrming a speciﬁc role for Akt and mTOR. Taken
together, the data indicate that Akt/mTOR mediate necropto-
sis signaling downstream of the necrosome assembly and
before the production of ROS and onset of plasmalemma
damage. The observation that concomitant inhibition of Akt
and mTOR together was required for maximal protection is
reminiscent of our ﬁndings in the CCI model, and suggests
divergent roles for Akt and mTOR in necroptotic signaling
inneuronalcells.Incontrast,Aktactivationwasnotinvolvedin
apoptosis of HT22 cells treated with TNF and CHX
(Figure 4e).
In the current study, antagonism of Akt and mTOR together
was required to maximally inhibit necroptosis in HT22 cells.
These ﬁndings are in agreement with our previous in vivo
study in which Akt and mTOR inhibitors together were
required to reduce necrotic cell death and improve postinjury
cognitive function after cerebral contusion in mice.
11 Thus,
regulation of necroptosis by Akt and mTOR together may be a
unique property of neuronal cells, or may depend on the exact
stimulus used to initiate necroptosis. Akt is activated and is
essential fornecroptosis in mouse L929 ﬁbroblasts stimulated
with TNFa or zVAD, but not for necroptosis of Fas-associated
protein with death domain-deﬁcient Jurkat T lymphocytes
treated with TNFa.
23 In mouse lung ﬁbroblasts and macro-
phages, Akt exhibited control over necroptosis-associated
TNFa production but did not have a role in cell death.
23
Figure 7 RIPK1–RIPK3 complex assembly occurs upstream of Akt/mTOR
activation and reactive oxygen species (ROS) generation after TNFa/zVAD
treatment. Interaction between RIPK1–RIPK3 (a) and RIPK1–Akt (b) was detected
by immunoprecipitation (IP) and western blot analysis. (c) RIPK1–p-Akt-473
interaction (arrow) was also detected at 2h after TNF/ZVAD (TZ) treatment.
Detection of p-Akt-473 was abolished by pretreatment with necrostatin-1 (TZN,
30uM). Control experiments showed the presence of RIPK1 in immunoprecipitants
from all of the groups except those immunoprecipitated with irrelevant IgG. DMSO,
dimethylsulfoxide control. Data are representative of three independent
experiments
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Cell Death and DiseaseThus, Akt activation mediates necroptosis in some but not all
non-neuronal cell types, and as such is not a uniform deﬁning
feature ofnecroptosis. This idea issupported by data showing
partial or complete inhibition of cell death by various
antioxidant agents and inhibitors of oxidative stress enzymes
(Figure 3c). Akt is activated during necroptosis in Jurkat cells
but ROS production does not occur, and Akt inhibitors block
TNF production but not cell death in this line.
2,23 Thus, no
simple relationship exists between Akt/mTOR activation,
ROS production and necroptosis in all cell types.
IP studies performed herein suggest that phosphorylation
ofAktmayberequiredforitsincorporationintothenecrosome
complex, as treatment with necrostatin-1 abolished detection
of phospho–Akt–473–RIPK1 interaction. These ﬁndings
suggest that Akt phosphorylation might regulate necroptosis
at the level of the necrosome. In the case of L929 cells, Akt
Ser-473 was not increased or involved in cell death; however,
plasmalemma localization and selective phosphorylation of
Akt Thr-308 was required to link RIPK1 to downstream JNK
signaling, autocrine TNFa production, and death.
23 Although
the exact mechanism of Thr-308 phosphorylation remains
unknown, inhibition of phosphatase 2A (a phosphatase that
dephosphorylates Thr-308; 45MnA) had no effect.
23 In vitro,
recombinant RIPK1 can phosphorylate Akt on Thr146,
195/197, 435, and Ser381 but whether Akt is an endogenous
substrate of RIPK1 is not clear.
23 Further studies are needed
to better understand how Akt is regulated by phosphorylation
during necroptosis.
Prevailing wisdom assigns a prosurvival role for Akt in CNS
injury paradigms including stroke and traumatic brain
injury.
29–40 Antiapoptotic activity of Akt has been well
documented, through a number of mechanisms including
inhibition of caspase 9, Bad, and GSK-3b, and induction of
mitochondrial hexokinase and nuclear factor kappa B-depen-
dent antiapoptotic gene expression.
41–43 Nonetheless, sev-
eral recent reports illustrate an emerging role for Akt as a
‘death kinase’ and a key regulator of programmed necrosis,
including neuronal cell types,
44 depending on injury context.
Activationofphosphatidylinositol3kinase/Akthasbeenlinked
to cytotoxic cell death
45–48 and nuclear translocation of Akt
has been reported to sensitize cancer cells to death by
chemotherapeutic agents.
49,50 Akt inhibitors also protect
cultured neurons against photodynamic induced necrosis.
44
Data from the current study raise the question of which Akt/
mTOR substrates might be critical regulators of necroptosis in
neuronal cells. Our data suggest a possible role for mTOR
complex1-dependent regulation as previously reported by
McNamara et al.,
23 as well as the Akt substrates FOXO1,
GSK-3b, and others. Although further studies are needed to
determine the speciﬁc mediators downstream of Akt and
mTOR, taken together the present data and our previous
report
11 suggest that Akt may promote necrosis in neuronal
cell types following acute CNS injury.
How might Akt promote necrotic death? Although limited
activation of Akt is antiapoptotic, sustained Akt activity may
promote cell death by a number of distinct mechanisms.
Strong activation of Akt increases oxygen consumption by
increasing glycolysis and oxidative phosphorylation, resulting
in generation of ROS and oxidative stress.
24,42 Sustained Akt
activation also induces phosphorylation of forkhead box
subclass O (FOXO) transcription factors required for upregu-
lation ofantioxidantdefenses suchasmanganesesuperoxide
dismutase, catalase and sestrin-3.
51,52 Phosphorylated
FOXO transcription factors bind to 14-3-3 protein and are
excluded from the nucleus, thus rendered transcriptionally
inactive,
53 and sustained phosphorylation promotes their
proteosomal degradation.
54,55 Our ﬁnding that the inhibition
of Akt/mTOR strongly inhibited phosphorylation of FOXO1,
reduced generation of ROS and inhibited death in HT22 cells
stimulated to necroptosis suggests that Akt/mTOR activation
may increase lethal oxidative stress after acute injury
to neuronal cells. Finally, sustained Akt activation can
constitutively activate cyclin-dependent kinase 2 leading to
its cytoplasmic sequestration, cell cycle arrest at G2-M, and
induction of cell death.
56,57 Future studies aimed at pinpoint-
ing the exact mechanisms of Akt/mTOR-induced necroptosis
are warranted as Akt and mTOR may not be optimal
therapeutic targets for neuroprotection because of their
protean functions in cells.
Herein, we show that Akt and mTOR together account for
B50% of the cell death in the conditions used in necroptosis
assays. The other mechanism(s) that account for the
remainder of necroptotic cell death remain to be discovered.
A JNK inhibitor reduced necroptosis in HT22 cells by B50%;
however, we did not observe an additive effect of Akt/mTOR/
JNK inhibitors and no effect of extracellular-regulated
kinase or P38 mitogen-activated protein kinase (MAPK)
inhibition, consistent with a similar lack of a role for these
MAPK in necroptosis of non-neuronal cell types.
23,28
Interestingly, we previously reported that intracerebroventri-
cular administration of necrostatin-1 reduced necrotic cell
death in dentate gyrus and cortex after CCI in mice.
3
However, these brain regions were not protected by
Akt/mTOR inhibitors in our subsequent study,
11 consistent
with the ﬁndings of the current study that necrostatin-1 is fully
and Akt/mTOR inhibitors only partially protective against
necrotic cell death in HT22 cells.
In conclusion, we demonstrate for the ﬁrst time a role for
Akt/mTOR signaling governing necroptosis in a neuronal cell
line. The data are consistent with a need for dual inhibition of
Akt and mTOR to reduce traumatic brain cell death in vivo.
11
Elucidation of additional necroptosis signaling mechanisms
downstream of necrosome assembly will be important to fully
understand how necroptosis is regulated in neuronal cells.
Such information is likely to yield new therapeutic targets to
reduce cell death and improve functional outcome after
stroke, traumatic brain injury, and other forms of acute
CNS injury.
Materials and Methods
Reagents. The following materials were purchased from commercial compa-
nies: TNFa (PeroTech; Rocky Hill, NJ, USA); pan-caspase inhibitor z-VAD-fmk
(Abcam, Cambridge, MA, USA). InSolution Akt Inhibitor viii isozyme-selective,
Akti-1/2 and InSolution rapamycin were obtained from Calbiochem (San Diego,
CA, USA). MitoSox Red was obtained from Invitrogen (Carlsbad, CA, USA).
Hoechst 33258, butylated hydroxyanisole (BHA) and rotenone were obtained from
Sigma (St. Louis, MO, USA). Nec-1 (5-(7-chloro-1H-indol-3-ylmethyl)-3-methyli-
midazolidine-2,4-dione), the inactive analog of necrostatin-1 analog (Nec-1i;
5-(7-chloro-1H-indol-3-ylmethyl)imidazolidine-2,4-dione),
3,12,13 was a kind gift from
Dr. Greg Cuny. LOX-1 was obtained from Chembridge (compound 5680672; San
Diego, CA, USA), and Bai was from Cayman Chemicals (Ann Arbor, MI, USA).
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anti-p-GSK-3b, anti-p-mTOR, anti-p-S6, anti-mTOR, anti-Akt1, anti-Akt2, anti-
Akt3, and anti-Akt from Cell Signaling (Danvers, MA, USA); anti-RIPK1 from BD
Transduction Laboratories (Lexington, KY, USA); anti-RIPK3 from ProSci
Incorporated (San Diego, CA, USA); anti-HMGB1 and b-actin were obtained
from Abcam.
Cell culture and treatment protocols. HT22 murine hippocampal
neuronal cells were maintained in Dulbecco’s modiﬁed essential medium
supplemented with 10% (v/v) FBS and antibiotics (penicillin–streptomycin) and
incubated at 371C under 5% CO2. To test the effects of necrostatin-1 (30mM),
Nec-1i (30mM), BHA (100 and 10mM), LOX-1(5mM), Bai (10mM), Akt inhibitor
VIII (10mM), and rapamycin (100nM), cells were pretreated with each of the
reagents at the mentioned concentrations for 15min before the addition of TNFa
(1ng/ml) and zVAD (50mM). Control groups were treated with vehicle (DMSO)
only. For experiments examining apoptosis, HT22 cells were treated for 2 or 18h
with TNF (10ng/ml) and CHX (10mg/ml).
Detection of cell death using propidium iodide. Propidium iodide
(1mg/ml; Sigma) and Hoechst 33258 (10mg/ml; Sigma) were added to media and
incubated with HT22 cells for 5min. For quantiﬁcation of PIþ cells, photographs
were randomly taken from three individual  200 ﬁelds per well. There were three
wells per experimental condition. PI
þ cells were expressed as a percentage of
Hoechst
þ cells.
Immunocytochemistry. For HMGB1 staining, HT22 cells were ﬁxed with
4% paraformaldehyde in PBS for 15min at room temperature and permeabilized
with 0.1% Triton X-100 in PBS. After blocking with 1% bovine serum albumin, cells
were incubated with primary antibody to HMGB1 (1:100; Cell Signaling) overnight
at 41C, followed by incubation with a ﬂuorescein isothiocyanate-conjugated goat
anti-rabbit IgG (1:500) at room temperature for 1h. Hoechst dye was used for
nuclear staining.
Transmission electron microscopy. HT22 cells were ﬁxed in PBS
containing 2% paraformaldehyde/2% glutaraldehyde for 60min. After washing in
the same buffer, cells were gently scraped off with a rubber policeman,
centrifuged, and postﬁxed with 1% OsO4, 0.8% potassium ferricianide, and 5mM
CaCl2 in 0.1M cacodylate buffer. Samples were washed twice in the same buffer,
dehydrated in acetone and embedded in PolyBed 812. Ultrathin sections were
stained with uranyl acetate and lead citrate and observed in a FEI Morgagni
transmission electron microscope operating at 80kV.
RNA interference. siRNA for mouse Akt1, Akt2, mTOR, and RIPK3
(ON-TARGETplus SMARTpool) was obtained from Thermo Fisher Scientiﬁc
(Waltham, MA, USA). Twenty nmol of siRNA with lipofectamine 2000 was
transfected into HT22 cells. The same concentration of nontarget siRNA
(from Thermo Fisher Scientiﬁc) was used as control. Cells were cultured for
3 days and targeted gene expression was examined by western blot.
Western blotting. Cells were lysed in radio-immunoprecipitation assay
buffer (10mM HEPES buffer, pH 7.6, 42mM KCl, 5mM MgCl2, 1% SDS,
1mM phenylmethylsulfonylﬂuoride, 1mM EDTA (ethylenediaminetetraacetic acid),
1mM ethylene glycol tetraacetic acid, 1mM dithiothreitol, 1.5mM pepstatin, 2mM
leupeptin, and 0.7mM aprotinin). Protein concentration was determined using the
DCTM protein assay (Bio-Rad, Hercules, CA, USA). Thirty to ﬁfty micrograms of
protein was applied for polyacrylamide gel electrophoresis. The primary antibodies
against HMGB1 (1:500), RIPK3 (1:1000), Akt1 (1:500), Akt2 (1:500), Akt3
(1:500), Akt (1:500), mTOR (1:500), phospho (Ser-473)-Akt (1:500), phospho
(Ser308)-Akt (1:500), phospho (Ser9)-GSK-3b (1:1000), phospho (Ser235/236)-
S6 (1:1000), and phospho (ser2448)-mTOR (1:1000) were obtained from Cell
Signaling. Horseradish peroxidase conjugated secondary antibodies (1:10000)
were used for ECL-plus (GE Healthcare, Pittsburgh, PA, USA) detection. The
results were normalized to b-actin (1:5000).
Immunoprecipitation. For co-immunoprecipitation experiments, a total of
1.8mg of protein from HT22 cells was used. Cells were stimulated with TNFa
(1ng/ml) and zVAD (50mM) in the presence or absence of Necrostatin-1 (30mM),
Akt Inhibitor VIII 10mM), or rapamycin (100nM) for 2h. Cells were collected,
washed in PBS and lysed in a buffer containing 20mM Tris-HCl (pH 8), 137mM
NaCl, 10% glycerol, 1% Nonidet P-40 (NP-40), 2mM EDTA, and protease inhibitor
cocktail. Precleaning was achieved with 50ml of protein A/G agarose beads (Santa
Cruz, Dallas, TX, USA) for 1h, and lysates were incubated overnight at 41Ci n
presence of 50ml of protein A/G agarose or magnetic beads and 1–2mg mouse
anti-RIP1 antibody (BD Transduction) before analysis by western blotting.
The same amount of irrelevant mouse IgG (Santa Cruz) was used to control for
nonspeciﬁc IgG binding to RIPK1.
Measurement of ROS. HT22 cells were incubated with 5uM MitoSOX Red
for 10min at 371C. Cells were washed in PBS and analyzed by ﬂuorescence
microscopy. Mitosox-positive cells were expressed as a percentage of total cells in
3–6  200 ﬁelds/well, three wells per experiment. Experiments were repeated
four times.
Statistical analysis. All values were expressed as mean±S.E.M. Data from
more than two groups were assessed by one-way ANOVA, followed by
Tukey’s multiple comparison test using Graph Pad Prism V software (La Jolla,
CA, USA). For all experiments, Po0.05 was considered statistically signiﬁcant.
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